Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
3 min read
Harpoon Therapeutics shares progress on HPN217 development with AbbVie
20 September 2023
Harpoon Therapeutics announced that AbbVie has offered a unique licensing opportunity for its HPN217 program, targeting BCMA, as per their Development and Option Agreement.
Drug Insights
4 min read
Pharmaceutical Insights: Nitrofurazone's R&D Progress and its Mechanism of Action on Drug Target
20 September 2023
This article summarized the latest R&D progress of Nitrofurazone, the Mechanism of Action for Nitrofurazone, and the drug target R&D trends for Nitrofurazone.
Valuable Targets
6 min read
Progress in Clinical Research of HDAC6 Inhibitors
20 September 2023
HDAC6 is the largest member of the HDAC family, consisting of 1215 amino acids.
Drug Insights
4 min read
Exploring Lorlatinib's Revolutionary R&D Successes
20 September 2023
This article summarized the latest R&D progress of Lorlatinib, the Mechanism of Action for Lorlatinib, and the drug target R&D trends for Lorlatinib.
Latest Hotspot
3 min read
The first patient of Vincerx Pharma's Phase 1 Clinical Tria of VIP943 has been administered
20 September 2023
Vincerx Pharma, Inc. declared that the initial patient in the Phase 1 clinical trial has received treatment with VIP943.
Drug Insights
4 min read
Decoding Iloperidone: A Comprehensive Study of its R&D Trends
20 September 2023
This article summarized the latest R&D progress of Iloperidone, the Mechanism of Action for Iloperidone, and the drug target R&D trends for Iloperidone.
Valuable Targets
6 min read
Progress in the Study of HIV-1 Integrase Inhibitors
20 September 2023
HIV-1 integrase is an enzyme that plays a crucial role in the replication of the human immunodeficiency virus (HIV-1) within the human body.
Drug Insights
3 min read
Deep Scientific Insights on Idarucizumab's R&D Progress
20 September 2023
This article summarized the latest R&D progress of Idarucizumab, the Mechanism of Action for Idarucizumab, and the drug target R&D trends for Idarucizumab.
Latest Hotspot
3 min read
Oscotec/ ADEL reveal FDA has granted the IND application clearance for ADEL-Y01 to treat Alzheimer's Disease
20 September 2023
Oscotec Inc. and ADEL Inc. has announced that the FDA has given the IND application approval for ADEL-Y01 to be used in the treatment of Alzheimer's Disease.
Drug Insights
5 min read
An In-depth Analysis of Glofitamab's R&D Progress and Mechanism of Action on Drug Target
20 September 2023
This article summarized the latest R&D progress of Glofitamab, the Mechanism of Action for Glofitamab, and the drug target R&D trends for Glofitamab
Valuable Targets
7 min read
Advances in the Application of HER2 Inhibitors in Tumors
20 September 2023
Human Epidermal Growth Factor Receptor 2 (HER2) is a member of the EGFR kinase family, which also includes HER1, HER3, and HER4.
Drug Insights
4 min read
Fezolinetant: Detailed Review of its Transformative R&D Success
20 September 2023
This article summarized the latest R&D progress of Fezolinetant, the Mechanism of Action for Fezolinetant, and the drug target R&D trends for Fezolinetant.